SAN DIEGO, March 11, 2011 /PRNewswire/ — Halozyme Therapeutics,
Inc. (Nasdaq:
HALO), a biopharmaceutical company developing and
commercializing products targeting the extracellular matrix
for the endocrinology, oncology, dermatology and drug delivery
markets, today reported financial results for the fourth quarter
and year ended December 31, 2010.
(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)
“I am energized and excited by the performance and advancements
that Halozyme delivered in 2010 as we executed on our broad
clinical development strategies for our rHuPH20 technology,” stated
Gregory I. Frost, Ph.D., Halozyme’s president and CEO. “Halozyme’s
research pipeline is positioned to achieve value inflection points
this year including the results of three Ultrafast Insulin studies
and the start of additional clinical trials for PEGPH20 in
pancreatic cancer and for HTI-501 to assess its potential utility
in cellulite. Our alliance partners should also demonstrate
substantial progress in 2011 for products that utilize our
technology as Baxter has stated it expects to file a BLA for HyQ
(immunoglobulin
subcutaneous) and Roche has stated it plans to announce top line
data from the pivotal Phase 3 trial for subcutaneous
Herceptin®.”
Fourth Quarter 2010 and Recent Business Highlights
Halozyme began patient dosing for an Ultrafast Insulin clinical
trial in type 1 diabetes patients who receive their insulin
treatment with a pump. We believe the faster-in and faster-out
profile of our Analog Insulin-PH20 makes it well suited to pump
applications because it should allow pat
‘/>”/>
SOURCE
